N
SAGE

Natixis’s Sage Therapeutics SAGE Stock Holding History

Natixis’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-95
Closed -$1.78K – 1129
2024
Q1 		$1.78K Sell
95
-30,905
-100% -$713K ﹤0.01% 951
2023
Q4 		$672K Hold
31,000
– – ﹤0.01% 582
2023
Q3 		$638K Buy
+31,000
New +$895K ﹤0.01% 571
2022
Q3 		– Sell
-35,200
Closed -$1.14M – 1164
2022
Q2 		$1.14M Buy
+35,200
New +$1.18M ﹤0.01% 793
2021
Q4 		– Sell
-34,900
Closed -$1.55M – 1335
2021
Q3 		$1.55M Buy
+34,900
New +$1.6M 0.01% 784

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Natixis's SAGE Position: Q2 2024 in Review

Natixis sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 95 shares — an estimated $1.78K sold.

Natixis first reported a position in SAGE in Q3 2021 and held it in 5 quarters. The position peaked at $1.55M in Q3 2021. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • Natixis reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Natixis sold 95 Sage Therapeutics shares in Q2 2024, an estimated $1.78K.
  • Natixis first reported a position in Sage Therapeutics in Q3 2021 and held it in 5 quarters.
  • Natixis's Sage Therapeutics position peaked at $1.55M in Q3 2021.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.